Slide 1: Q1 FY-2026 Earnings Call
Q1 FY-2026 Earnings Call (o) Enabling the Future of Medicine
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the
Slide 3: Cryoport Snapshot – By the Numbers
Cryoport Snapshot – By the Numbers Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain $47.8M $192-$196M 46% ($0.6M) +16% Organic Growth +9-11% Organic Growth +42bps YoY $2.2M Improvement YoY Q1 FY2026 FY2026 Q1 FY2026 Q1 FY2026 Adjusted R
Slide 4: The Cryoport Platform: Services & Products
The Cryoport Platform: Services & Products Core services and products supporting the management of critical biomaterials Life Sciences Services 56% Life Sciences Products 44% +18% YoY +15% YoY Q1 FY2026 Q1 FY2026 BioLogistics IntegriCell® BioServices BioStorage Cryogenic Systems (Launched in 2024) (
Slide 5: Cryoport Snapshot – Revenue Mix
Cryoport Snapshot – Revenue Mix Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain Q1 FY2026 Revenue Type Geography Cell & Gene Therapy Revenue 8% 19% 41% 44% 56% 59% 73% Services Americas Clinical Products EMEA Commercial APAC © 2026 CRY
Slide 6: Q1 2026 Revenue Drivers
Q1 2026 Revenue Drivers Strong double-digit growth across the platform of products and services +21% +26% Commercial Cell BioServices & & Gene Therapy Revenue +18% Biostorage Revenue +15% Life Sciences Services Revenue Life Sciences Products Revenue Q1 FY2026 Revenue Strong Growth +16% Across All Se
Slide 7: Revenue Q1-FY2026
Revenue Q1-FY2026 © 2026 CRYOPORT, INC. 7
Slide 8: Driving Bottom-Line Improvement in Q1 2026
Driving Bottom-Line Improvement in Q1 2026 with a Strong Balance Sheet to Support Long-term Strategy 45.8% $(0.6M) $403.6M Adjusted EBITDA Cash and Gross Margin from Continuing Short-Term Operations Investments © 2026 CRYOPORT, INC. 8
Slide 9: Key Revenue Growth Drivers - Cell and Gene Therapies (CGT)
Key Revenue Growth Drivers - Cell and Gene Therapies (CGT) Commercial CGT Revenue Clinical Trial CGT Revenue ($ in millions) ($ in millions) $12.9 $9.1 $11.0 $7.2 +26% +18% YoY YoY Q1 2025 Q1 2026 Q1 2025 Q1 2026 © 2026 CRYOPORT, INC. 9
Slide 10: Life Sciences Services Key Revenue Growth Drivers
Life Sciences Services Key Revenue Growth Drivers BioLogistics Revenue BioStorage/BioServices ($ in millions) Revenue ($ in millions) $21.7 $18.5 $5.2 +17% $4.3 YoY +21% YoY Q1 2025 Q1 2026 Q1 2025 Q1 2026 © 2026 CRYOPORT, INC. 10
Slide 11: Patients First: Supporting the Therapies of Tomorrow
Patients First: Supporting the Therapies of Tomorrow Clinical Trials Supported, by Trial Phase 21 Commercial Therapies Supported Phase I Phase II Phase III 766 アクーゴ 760 701 AKUUGO® 675 654 86 91 602 81 79 82 74 361 357 311 321 300 273 255 275 282 299 313 318 ® 2021 2022 2023 2024 2025 Q1 2026 CGT In
Slide 12: Cryoport - the Leading Service Provider for CGT
Cryoport - the Leading Service Provider for CGT Deeply embedded with customers and partners with significant barriers to entry Global CGT Clinical Trials(1) Global Commercial Therapies(2) Number & share of global, active cell & gene therapy clinical trials (excl. pre-clinical) Revenue from commercia
Slide 13: Growing Clinical Trial Count
Growing Clinical Trial Count Spring-loaded Pipeline for Commercial Revenue Growth © 2026 CRYOPORT, INC. 13
Slide 14: Supporting 21 Commercial Cell and Gene Therapies Globally
Supporting 21 Commercial Cell and Gene Therapies Globally アクーゴ AKUUGO® ® © 2026 CRYOPORT, INC. 14
Slide 15: Funding Environment Strengthening
Funding Environment Strengthening Total Monthly Biopharma Financing ($M) Biopharma Equity Investments ($B) Total biopharma funding has remained strong with April 2026 funding up ~422% year-over-year and up ~72% month-over-month. April’s funding was driven by 13 public transactions greater than $200
Slide 16: Statement of Operations
Statement of Operations Q1-2026 © 2026 CRYOPORT, INC. 16
Slide 17: Adjusted EBITDA
Adjusted EBITDA © 2026 CRYOPORT, INC. 17
Slide 18: Balance Sheet 03/31/2026
Balance Sheet 03/31/2026 © 2026 CRYOPORT, INC. 18
Slide 19: Regulatory Discipline and Compliance
Regulatory Discipline and Compliance Assurance of global regulatory compliance End-to-end control Chain-of-custody, chain-of- FDA-registered and audit- ISO 21973 Certified mitigating risk from identity, chain-of-condition, ready operations across vendor hand-offs and full traceability global facilit
Slide 20: Cryoport: Setting Industry Standards for the CGT Supply Chain
Cryoport: Setting Industry Standards for the CGT Supply Chain Integration is the Engine that Drives Scale Manufacturing © 2026 CRYOPORT, INC. 20
Slide 21: Comprehensive Global Capabilities
Comprehensive Global Capabilities Global Supply Chain Center BioLogistics BioServices IntegriCell® BioStorage MVE Americas EMEA APAC HQ Expanding Capabilities Globally Paris, FRANCE (H2’25) Santa Ana, USA (Expected H2’26) Tampa, USA (Expected late ’27) Global Supply Chain Center Global Supply Chain
Slide 22: FDA Regulatory Shift Unlocks CAR-T Growth
FDA Regulatory Shift Unlocks CAR-T Growth Burden Decreased Risk Evaluation and Mitigation Strategy Makes it easier for physicians to (REMS) requirements removed administer CAR-Ts Shortened required patient proximity to Promotes CAR-T administration outside treatment facility from 4 weeks to 2 weeks
Slide 23: Why Cryoport?
Why Cryoport? Market leader in temperature-controlled supply chain services Scalable platform with expanding suite of integrated services Deeply embedded in majority of cell & gene clinical and commercial therapies Double-digit services revenue growth and stabilizing product revenue Significant marg
Slide 24: Join us in “Enabling the Future of Medicine”
Join us in “Enabling the Future of Medicine ” Jerrell Shelton Chief Executive Officer jshelton@cryoport.com https://www.cryoport.com/ https://ir.cryoportinc.com/